Structure via PubChem · Public domain (PubChem)
ニラパリブ
Sign in to saveAlso known as compound 56 [PMID 19873981], MK 4827, MK-4827, Niraparib, Zejula
Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is taken by mouth. It is a PARP inhibitor.
Key facts
- Drug.legal_AU
- S4
- Drug.image
- Niraparib.svg
- Drug.image_class
- skin-invert-image
- Drug.caption
- Above: molecular structure of niraparib Below: 3D representation of a niraparib molecule
- Drug.image2
- Niraparib 3D.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Zejula
- Drug.MedlinePlus
- a617007
- Drug.DailyMedID
- Niraparib
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- XK02
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C19H20N4O
- Molecular weight
- 320.4 g/mol
- IUPAC name
- 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
- SMILES
- C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
- InChIKey
- PCHKPVIQAHNQLW-CQSZACIVSA-N
- XLogP
- 2.2
- Polar surface area
- 72.9 Ų
- H-bond donors
- 2
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2017
- Admin. routes
- oral
- Indications
- ovarian carcinoma, neoplasm, prostate adenocarcinoma, Hereditary breast and ovarian cancer syndrome
via ChEMBL · EBI
Research
986 papers- Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2024
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.The New England journal of medicine · 2019
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.The New England journal of medicine · 2016
- Niraparib.2012
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 320.164
Show 7 more facts
- chemical formula
- C₁₉H₂₀N₄O
- canonical SMILES
- C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
- subject has role
- PARP inhibitor
- isomeric SMILES
- NC(=O)C1=CC=CC2=CN(N=C12)C3=CC=C(C=C3)[C@@H]4CCCNC4
- NCI Thesaurus ID
- C80059
- medical condition treated
- ovarian cancer
- Commons category
- Niraparib
Sources (7)
via Wikidata · CC0
Article · 日本語
ニラパリブ（Niraparib、開発コード：MK-4827）は、上皮性卵巣癌、卵管癌、原発性腹膜癌の治療に用いられる経口抗癌剤である。日本では卵巣癌の治療・維持療法で用いられる。類薬のオラパリブはBRCA遺伝子変異陽性の患者に使用されるが、ニラパリブはBRCA遺伝子変異の有無に拘らず使用可能である。 米国と欧州で2017年に、日本で2020年に承認された。
Abstract from DBpedia / Wikipedia · CC BY-SA